Opticyte Secures $4.6 Million in Funding to Develop First Cell O2 Monitor for Reducing Organ Failure
Published
SEATTLE--(BUSINESS WIRE)--Opticyte, Inc, a medical device innovator developing proprietary advanced algorithms and tailored optical spectroscopy technology to measure and detect low oxygen levels in cells to prevent organ failure, announced the recent culmination of private capital and grant funding. The $4.6MM in funding is enabling Opticyte to address sepsis–the primary cause of organ failure and the most expensive condition to treat for in the U.S. healthcare system. Opticyte’s real-time tec
Full Article